IBD--MUCOSA-SPECIFIC REGULATION OF IFN-GAMMA PRODUCTION

IBD--IFN-γ产生的粘膜特异性调节

基本信息

  • 批准号:
    6687840
  • 负责人:
  • 金额:
    $ 30.6万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-03-01 至 2005-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: (Adapted from the Applicant's Abstract): T-cell production of IFN-gamma plays an essential role in disease initiation and severity of disease in animal models and Crohn's disease. Mucosal T-cells are different from peripheral T-cells in several ways. Mucosal T-cells are muted responders to activation via the T-cell receptor and are CD2 pathway dominant. During the previous award period the investigators used their ability to transfect primary T-cells to show unique mucosa-specific mechanisms by which T-cells produced Th1 cytokines. They demonstrated a role for AP1 in CD2 transactivation of the IL-2 gene. They showed that enhanced IL-2 production by CD2/CD28 co-activated peripheral T-cells occurs through mRNA stabilization and trans-activation in peripheral T-cells, however, in mucosal T-cells this effect can be solely the result of mRNA stabilization. This difference is due to the lack of activation of the AP1 and CD28 response elements in the IL-2 promotor in mucosal cells. They demonstrated several mucosal-specific mechanisms of IFN-gamma regulation and identified a unique role for TNF-alpha in mucosal T-cell IFN-gamma regulation. They defined the lamina propria mononuclear cell factor which can prime T-cells to respond to TNF-alpha. Furthermore, they demonstrated different cis elements in the IFN-gamma promotor that are used for transactivation of the IFN-gamma gene and mucosal T-cells as compared to peripheral T-cells. Finally, they demonstrated for the first time the enhancer function of the first intronic region of the IFN-gamma gene that involves the JAK/STAT pathway in mucosal T-cells but not in peripheral T-cells. Because of the vital importance of IFN-gamma in disease related mucosal inflammation yet its critical role for host defense, the knowledge of mucosa-specific targets, which would selectively attenuate mucosal IFN-gamma production without eliminating, would be a significant accomplishment. The overall objective of this continuation proposal is to more precisely define the mucosal specific regulatory pathways that are important for IFN-gamma regulation in T-cells and to use this knowledge to design approaches to modify IFN-gamma production in a mucosa-specific manner. This will be accomplished by the following specific aims: To identify through fine promotor analysis positive and negative cis-regulatory regions within the IFN-gamma promotor in which transcriptional regulation in lamina propria mononuclear cells differ from that in peripheral blood lymphocytes focusing on the previously identified regions of -204 to -108 (enhancer) and -528 to -204 base pair (repressor). To determine the mucosa-specific mechanisms of regulating the first intronic region of the IFN-gamma gene. From the results of Aim 1 and Aim 2 design molecular approaches including transfection of antisense oligonucleotides and or dominant negative transacting factors to attenuate in vitro IFN-gamma promotor expression in a mucosal-specific manner.
描述:(改编自申请人的摘要):T细胞的生产 干扰素-γ在疾病的发生和严重程度中起着重要作用。 在动物模型和克罗恩病中。粘膜T细胞不同于 外周T细胞以几种方式。粘膜T细胞是沉默的反应者 激活途径主要通过T细胞受体和CD2途径。在.期间 在之前的获奖期间,研究人员利用他们的能力将 T细胞显示独特的粘膜特异性机制,通过T细胞产生Th1 细胞因子。他们证明了AP1在CD2反式激活IL-2中的作用 吉恩。他们表明,CD2/CD28共同激活可增强IL-2的产生 外周T细胞通过mRNA稳定和反式激活而发生 然而,在粘膜T细胞中,外周T细胞的这种作用可能仅仅是 MRNA稳定的结果。这种差异是由于缺乏激活造成的 黏膜细胞IL-2启动子中的AP1和CD28反应元件。 他们展示了几种黏膜特异性的干扰素-γ调节机制。 并确定了肿瘤坏死因子-α在粘膜T细胞干扰素-γ中的独特作用 监管。他们定义了固有层单个核细胞因子,它可以 激发T细胞对肿瘤坏死因子-α的反应。此外,他们表现出了不同的 干扰素-γ启动子中用于反式激活的顺式元件 干扰素-γ基因与粘膜T细胞和外周T细胞的比较。最后, 他们首次展示了第一个 干扰素-γ基因内含子区域,涉及JAK/STAT途径 粘膜T细胞,而外周T细胞不表达。因为至关重要的是 干扰素-γ在疾病相关性粘膜炎症中的作用 宿主防御,粘膜特异性靶点的知识,这将选择性地 在不消除的情况下,减弱粘膜中干扰素-γ的产生,将是一种 取得了重大成就。这项延续提案的总体目标是 是更准确地定义黏膜特异性调节通路,这些调节通路是 对T细胞中干扰素-γ的调节很重要,并利用这一知识 设计以黏膜特异性方式修饰干扰素-γ产生的方法。 这将通过以下具体目标来实现:通过 精细的启动子分析正面和负面顺式调控区域 干扰素-γ启动子在固有层转录调控中的作用 单个核细胞与外周血淋巴细胞不同,主要集中在 先前确定的-204至-108(增强子)和-528至-204区域 碱基对(抑制子)。为了确定粘膜特异性的机制, 调节干扰素-γ基因的第一内含子区域。从以下结果来看 目标1和目标2设计包括反义基因转染的分子方法 寡核苷酸和或显性负性交易因子在 体外以黏膜特异性方式表达干扰素-γ启动子。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stephan R. Targan其他文献

Serial 6-mercaptopurine (6-MP) metabolite measurements in combination with dose escalation unmasks an important biochemical explanation for "6-MP resistance"
  • DOI:
    10.1016/s0016-5085(00)85698-x
  • 发表时间:
    2000-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Marla C. Dubinsky;Philip V. Hassard;Lori Y. Kam;Maria T. Abreu;Ernest G. Seidman;Stephan R. Targan;Eric A. Vasiliauskas
  • 通讯作者:
    Eric A. Vasiliauskas
Thioguanine (6-TG): A therapeutic alternative in a subgroup of IBD patients failing 6-mercaptopurine (6-MP)
  • DOI:
    10.1016/s0016-5085(00)85701-7
  • 发表时间:
    2000-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Marla C. Dubinsky;Philip V. Hassard;Maria T. Abreu;Lori Y. Kam;Ernest G. Seidman;Stephan R. Targan;Eric A. Vasiliauskas
  • 通讯作者:
    Eric A. Vasiliauskas
704 – Preoperative Serum Vedolizumab Levels Do Not Impact Postoperative Outcomes in Inflammatory Bowel Disease
  • DOI:
    10.1016/s0016-5085(19)37178-1
  • 发表时间:
    2019-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Aaron B. Parrish;Karen Zaghiyan;Nicole Lopez;Gil Melmed;Dermot McGovern;Anjali Jain;Carol Landers;Stephan R. Targan;Phillip Fleshner
  • 通讯作者:
    Phillip Fleshner
369: NOVEL ASSOCIATIONS OF SARCOPENIA WITH CLINICAL, RADIOGRAPHIC, BLOOD PARAMETER, AND POLYGENIC RISK SCORE (PRS) MEASURES IN CROHN'S DISEASE (CD)
  • DOI:
    10.1016/s0016-5085(22)60195-1
  • 发表时间:
    2022-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Shishir Dube;Norman Gellada;Dalin Li;Talin Haritunians;Phillip Gu;Shaohong Yang;Gregory J. Botwin;Stephan R. Targan;Damini Dey;Yaniv Raphael;Cindy Kallman;Dermot P.B. Mcgovern
  • 通讯作者:
    Dermot P.B. Mcgovern
Sa1879 - UBE2L3, ANCA, ASCA, and CBIR1 are Associated with Mechanisms of non-Response to Anti-TNF in IBD Patients with Adequate Drug Levels
  • DOI:
    10.1016/s0016-5085(17)31514-7
  • 发表时间:
    2017-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Leilei Zhu;Gil Melmed;Xiaofei Yan;Talin Haritunians;David Q. Shih;Eric Vasiliauskas;Andrew Ippoliti;Shervin Rabizadeh;Namita Singh;Stephan R. Targan;Zhenqiu Liu;Dalin Li;Dermot McGovern
  • 通讯作者:
    Dermot McGovern

Stephan R. Targan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Stephan R. Targan', 18)}}的其他基金

Mechanisms of TL1A-driven Paneth Cell dysfunction in IBD
IBD 中 TL1A 驱动的潘氏细胞功能障碍的机制
  • 批准号:
    10077845
  • 财政年份:
    2020
  • 资助金额:
    $ 30.6万
  • 项目类别:
Mechanisms of TL1A-driven Paneth Cell dysfunction in IBD
IBD 中 TL1A 驱动的潘氏细胞功能障碍的机制
  • 批准号:
    10539302
  • 财政年份:
    2020
  • 资助金额:
    $ 30.6万
  • 项目类别:
Mechanisms of TL1A-driven Paneth Cell dysfunction in IBD
IBD 中 TL1A 驱动的潘氏细胞功能障碍的机制
  • 批准号:
    10311509
  • 财政年份:
    2020
  • 资助金额:
    $ 30.6万
  • 项目类别:
Molecular characterization of the role of RNASET2 in Severe Crohn's Disease
RNASET2 在严重克罗恩病中作用的分子表征
  • 批准号:
    10021036
  • 财政年份:
    2019
  • 资助金额:
    $ 30.6万
  • 项目类别:
Molecular characterization of the role of RNASET2 in Severe Crohn's Disease
RNASET2 在严重克罗恩病中作用的分子表征
  • 批准号:
    10226172
  • 财政年份:
    2019
  • 资助金额:
    $ 30.6万
  • 项目类别:
Role of TRIF-Dependent TLR Signaling in Intestinal Mucosa
TRIF 依赖性 TLR 信号转导在肠粘膜中的作用
  • 批准号:
    10225616
  • 财政年份:
    2012
  • 资助金额:
    $ 30.6万
  • 项目类别:
INFLAMMATORY BOWEL DISEASE CENTER: CLINICAL DATA REPOSITORY - TISSUE PROCUREMENT
炎症性肠病中心:临床数据存储库 - 组织采购
  • 批准号:
    8174459
  • 财政年份:
    2009
  • 资助金额:
    $ 30.6万
  • 项目类别:
IBD: Mucosa Specific Regulation of IFN-gamma Production
IBD:粘膜对 IFN-γ 产生的特异性调节
  • 批准号:
    7921223
  • 财政年份:
    2009
  • 资助金额:
    $ 30.6万
  • 项目类别:
INFLAMMATORY BOWEL DISEASE CENTER: CLINICAL DATA REPOSITORY - TISSUE PROCUREMENT
炎症性肠病中心:临床数据存储库 - 组织采购
  • 批准号:
    7952200
  • 财政年份:
    2008
  • 资助金额:
    $ 30.6万
  • 项目类别:
CORE--TISSUE PROCUREMENT & DATA ANALYSIS & SERUM ANALYSIS
核心——纸巾采购
  • 批准号:
    7487329
  • 财政年份:
    2007
  • 资助金额:
    $ 30.6万
  • 项目类别:

相似海外基金

FUNCTION OF THE CD28 MOLECULE
CD28 分子的功能
  • 批准号:
    2182536
  • 财政年份:
    1992
  • 资助金额:
    $ 30.6万
  • 项目类别:
FUNCTION OF THE HUMAN CD28 MOLECULE
人类 CD28 分子的功能
  • 批准号:
    3303619
  • 财政年份:
    1992
  • 资助金额:
    $ 30.6万
  • 项目类别:
FUNCTION OF THE CD28 MOLECULE
CD28 分子的功能
  • 批准号:
    2182535
  • 财政年份:
    1992
  • 资助金额:
    $ 30.6万
  • 项目类别:
FUNCTION OF THE HUMAN CD28 MOLECULE
人类 CD28 分子的功能
  • 批准号:
    3303618
  • 财政年份:
    1992
  • 资助金额:
    $ 30.6万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了